ICCM

IceCure Medical Ltd
CAPPED RATING

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

IceCure Medical Ltd (ICCM) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Momentum (F). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
B
Factor Score 3.4 / 5.0
Growth
B+
Factor Score 3.8 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
F
Factor Score 0.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.2
EV / EBITDA 0.6
Rev Growth YoY 72.8%
Gross Margin 36.1%
Price Return 3M -75.3%
Price Return 12M -96.6%
Catalyst Signal 0.00
Market Cap $3.4M
TTM Revenue $3.9M
Price / Sales 0.9
ROE -228.3%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 B (3.4) B+ (3.8) C+ (2.7) F (0.4) C+ (2.6) C+ (2.6)
2026-11-05 B (3.4) A- (3.9) C+ (2.8) F (0.4) C+ (2.7) C+ (2.6)
2026-10-29 B (3.3) B+ (3.8) C+ (2.8) F (0.5) C+ (2.7) C+ (2.6)
2026-10-22 B (3.3) B+ (3.8) C+ (2.8) F (0.5) C+ (2.6) C+ (2.6)
2026-10-15 B (3.4) B+ (3.8) C+ (2.8) F (0.4) C+ (2.6) C+ (2.6)
Page 1 of 3